Journal
DIAGNOSTICS
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics11112090
Keywords
atopic dermatitis; biologic agents; neuroimmune interactions; type 2 inflammation
Categories
Funding
- Foundation of Strategic Research Projects in Private Universities [S1311011]
- JSPS KAKENHI from the Ministry of Education, Culture, Sports, Science, and Technology, Japan [18K07396, 20H03568]
- Lydia O'Leary Memorial Pias Dermatological Foundation
- Grants-in-Aid for Scientific Research [20H03568, 18K07396] Funding Source: KAKEN
Ask authors/readers for more resources
Recent evidence on type 2 inflammation-associated itch in atopic dermatitis has been reported, highlighting the importance of neuroimmune interactions in research. Understanding bidirectional neuroimmune interactions is crucial in gaining insights into the pathogenesis of itch and its treatment. Improved management and treatment options for itch in atopic dermatitis are being explored through novel and targeted biologic agents in advanced clinical trials.
Accumulated evidence on type 2 inflammation-associated itch in atopic dermatitis has recently been reported. Crosstalk between the immune and nervous systems (neuroimmune interactions) is prominent in atopic dermatitis research, particularly regarding itch and inflammation. A comprehensive understanding of bidirectional neuroimmune interactions will provide insights into the pathogenesis of itch and its treatment. There is currently no agreed cure for itch in atopic dermatitis; however, increasing numbers of novel and targeted biologic agents have potential for its management and are in the advanced stages of clinical trials. In this review, we summarize and discuss advances in our understanding of type 2 inflammation-associated itch and implications for its management and treatment in patients with atopic dermatitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available